Treatment of aortic stenosis: new learnings for the decade

Friday October 9th 2020 – 13:15-14:30
EACTS Virtual Platform / Hall A / Room 116-117

Virtual Symposium

Place of surgical AVR in octogenarians and nonagenarians in 2020: state of the art.

Krzysztof Bartus
Jagiellonian University, Department of Cardiovascular and Transplant Surgery, John Paul II Hospital, Krakow (Poland)

Structural valve deterioration.
What is the next step after VARC 2 guidelines.

Philippe Pibarot
Quebec Heart and Lung Institute, Quebec (Canada)

Prevention of thromboembolic events following AVR: aspirin/anti vitamin K/NOAC. Where are we standing?

Nikolaos Bonaros
Cardiac Surgery Innsbruck Medical University (Austria)

INSPIRIS RESILIA aortic valve:
a clinical body of evidence.

Martin Andreas
Medical University of Vienna (Austria)

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, INSPIRIS, INSPIRIS RESILIA and RESILIA are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are property of their respective owners.

© 2020 Edwards Lifesciences Corporation. All rights reserved. PP--EU-0756 v1.0
Edwards Lifesciences • Route de l’Etraz 70, 1260 Nyon, Switzerland • edwards.com